Geode Capital Management
ORMP icon

Geode Capital Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Geode Capital Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.41M Buy
500,690
+476,408
+1,962% +$1.9M ﹤0.01% 3153
2026
Q1 		$82.6K Hold
24,282
– – ﹤0.01% 4177
2025
Q4 		$69.2K Hold
24,282
– – ﹤0.01% 4175
2025
Q3 		$64.1K Hold
24,282
– – ﹤0.01% 4237
2025
Q2 		$54.6K Sell
24,282
-1,173
-5% -$2.59K ﹤0.01% 4198
2025
Q1 		$54.5K Hold
25,455
– – ﹤0.01% 4182
2024
Q4 		$61.6K Hold
25,455
– – ﹤0.01% 4207
2024
Q3 		$62.1K Hold
25,455
– – ﹤0.01% 4219
2024
Q2 		$65.4K Hold
25,455
– – ﹤0.01% 4230
2024
Q1 		$74.3K Hold
25,455
– – ﹤0.01% 4240
2023
Q4 		$58.8K Buy
25,455
+4,546
+22% +$9.71K ﹤0.01% 4311
2023
Q3 		$54.6K Hold
20,909
– – ﹤0.01% 4401
2023
Q2 		$74.9K Buy
20,909
+2,779
+15% +$8.91K ﹤0.01% 4419
2023
Q1 		$39.5K Hold
18,130
– – ﹤0.01% 4568
2022
Q4 		$218K Hold
18,130
– – ﹤0.01% 4050
2022
Q3 		$117K Hold
18,130
– – ﹤0.01% 4499
2022
Q2 		$83K Sell
18,130
-303,029
-94% -$1.62M ﹤0.01% 4651
2022
Q1 		$2.78M Buy
321,159
+75,814
+31% +$777K ﹤0.01% 3086
2021
Q4 		$3.5M Sell
245,345
-1,626
-0.7% -$34K ﹤0.01% 3086
2021
Q3 		$5.43M Buy
246,971
+29,263
+13% +$498K ﹤0.01% 2862
2021
Q2 		$2.91M Buy
217,708
+200,751
+1,184% +$2.3M ﹤0.01% 3154
2021
Q1 		$172K Hold
16,957
– – ﹤0.01% 4161
2020
Q4 		$71K Hold
16,957
– – ﹤0.01% 4114
2020
Q3 		$44K Hold
16,957
– – ﹤0.01% 4036
2020
Q2 		$59K Hold
16,957
– – ﹤0.01% 3953
2020
Q1 		$51K Hold
16,957
– – ﹤0.01% 3920
2019
Q4 		$87K Hold
16,957
– – ﹤0.01% 3990
2019
Q3 		$54K Hold
16,957
– – ﹤0.01% 4054
2019
Q2 		$60K Buy
+16,957
New +$59.8K ﹤0.01% 4059

Other funds holding ORMP

Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Geode Capital Management's ORMP Position: Q2 2026 in Review

Geode Capital Management increased its Oramed Pharmaceuticals (ORMP) stake by 1,962% in Q2 2026, buying an estimated $1.9M and bringing the position to 500,690 shares worth $2.41M. The position accounts for ﹤0.01% of the portfolio, ranked #3153.

Geode Capital Management first reported a position in ORMP in Q2 2019 and has held it in 29 quarters since. The position peaked at $5.43M in Q3 2021. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • Geode Capital Management held 500,690 shares of Oramed Pharmaceuticals worth $2.41M as of Q2 2026.
  • Geode Capital Management bought 476,408 Oramed Pharmaceuticals shares in Q2 2026, an estimated $1.9M.
  • Oramed Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3153 holding.
  • Geode Capital Management first reported a position in Oramed Pharmaceuticals in Q2 2019 and has held it in 29 quarters since.
  • Geode Capital Management's Oramed Pharmaceuticals position peaked at $5.43M in Q3 2021.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.